← Leaderboards
Harpreet Singh Bhatia
University Of California, San Diego
$506,736
Attributed
$506,736
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $168.9K · FY2023–25$200K$150K$100K$50K$0
'23
'24
'25
Funding mix
By agency
NIH$506,736 · 1
By mechanism
K08$506,736 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Diego
Same institution · by research overlap
- Howard Feldman$27,033,634
- Steven Bark$735,403
- Calvin Yeang$887,760
- Brook Henry$8,903,411
- Vincent Scott Tagliabracci$5,770,068
Others in their field
Other Rising Stars on “Antifibrinolytic Agents”
- Christian Kastrup · Versiti Wisconsin, Inc.$2,182,730
- Ze Zheng · Medical College Of Wisconsin$368,556
- Lynn Marie Malec · Medical College Of Wisconsin$368,556
Research focus
Antifibrinolytic AgentsAntisense OligonucleotidesAortic Valve StenosisApolipoprotein B-100Apolipoprotein Lp(A+)AspirinAtherogenesisAtherosclerosisAtherosclerosis Risk In CommunitiesAwardBiometryBlack RaceBlood PlateletsBlood SpecimenCardiologyCardiovascular DiseasesCardiovascular Disorder PreventionCardiovascular Disorder RiskCardiovascular Risk FactorCardiovascular SystemCareerCareer DevelopmentClinicAmerican
Grant awards (3)
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)$168,912
K08 · FY2025 · HL · contact PI
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)$168,912
K08 · FY2024 · HL · contact PI
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)$168,912
K08 · FY2023 · HL · contact PI